Abstract:Methanogens are strictly anaerobic archaea metabolising by-products of bacterial fermentation into methane by using three known metabolic pathways, i.e. the reduction of carbon dioxide, the fermentation of acetate or the dismutation of methanol or methylamines. Methanogens described in human microbiota include only Euryarchaeota, i.e. Methanobrevibacter smithii, Methanobrevibacter oralis, Methanobrevibacter arbophilus, Methanobrevibacter massiliensis, Methanomassiliicoccus luminyensis, Methanosphaera stadtmanae and Ca. Methanomethylophilus alvus and Ca. Methanomassiliicoccus intestinalis. Methanogens are emerging pathogens associated with brain and muscular abscesses. They have been implicated in dysbiosis of the oral microbiota, periodontitis and peri-implantitis. They have also been associated with dysbiosis of the digestive tract microbiota linked to metabolic disorders (anorexia, malnutrition and obesity) and with lesions of the digestive tract (colon cancer). Their detection in anaerobic pus specimens and oral and digestive tract specimens relies on microscopic examination by fluorescence in situ hybridisation, specific DNA extraction followed by polymerase chain reaction (PCR)-based amplification of the 16S rRNA and mcrA gene fragments and isolation and culture in the supporting presence of hydrogen-producing bacteria. Diagnostic identification can be performed by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) and can be further completed by genotyping through multi-spacer sequencing and, ultimately, whole genome sequencing (WGS). Ornidazole derivatives, fusidic acid and rifampicin are the compounds to be included in in vitro susceptibility testing to complete the clinical workflow. Clinical microbiology laboratories should work toward developing cheap and easy protocols for the routine detection and identification of methanogens in selected specimens in order to refine the diagnosis of infections, as well as to expand the knowledge about this group of intriguing microorganisms.

Molecular methods for studying methanogens of the human gastrointestinal tract: current status and future directions

Recent findings in methanotrophs: genetics, molecular ecology, and biopotential

Current status and future developments of assessing microbiome composition and dynamics in anaerobic digestion systems using metagenomic approaches

Experimental approaches for defining functional roles of microbes in the human gut

Targeted isolation of Methanobrevibacter strains from fecal samples expands the cultivated human archaeome

METAGENOMICS IN STUDYING THE HUMAN GUT MICROBIOME Metagenomics : Revealing the diversity of the human gut microbiome

Application of Metagenomics in the Human Gut Microbiome

State of the Art in the Culture of the Human Microbiota: New Interests and Strategies

Methanobrevibacter smithii cell variants in human physiology and pathology: A review

Unveiling the Human Gastrointestinal Tract Microbiome: The Past, Present, and Future of Metagenomics

Application of metagenomics in the human gut microbiome.

Genomic Techniques Used to Investigate the Human Gut Microbiota

Expanding the cultivated human archaeome by targeted isolation of novel strains from fecal samples

Advances in the integration of metabolomics and metagenomics for human gut microbiome and their clinical applications

Functional and molecular approaches for studying and controlling microbial communities in anaerobic digestion of organic waste: a review

The human gut microbiome: current knowledge, challenges, and future directions

Exploring the Human Microbiome: The Potential Future Role of Next-Generation Sequencing in Disease Diagnosis and Treatment

Methanogens as emerging pathogens in anaerobic abscesses

Methanogen and human gut health-A review

Metagenomics approaches for studying the human microbiome

Methanobrevibacter oralis: a comprehensive review